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Abstract 
Purpose: To evaluate the activity of the ethanol leaf extract of Piper sarmentosum against 
toxoplasmosis.  
Methods: An in vitro anti-Toxoplasma study was conducted using Vero cells as a host for T. gondii. 
Clindamycin used as the reference drug. Light microscopy technique was used to study the in situ 
antiparasitic activity of T. gondii. Non-toxic concentrations of the ethanol extract for Vero cells were 
determined by methyl thiazolyl tetrazolium (MTT) cell proliferation. The presence of Toxoplasma gondii 
was observed by Giemsa staining.  
Results: The results showed that significant (p < 0.05) anti-toxoplasma activity of the ethanol extract, 
though lower than that of clindamycin (control drug), was achieved, with half-maximal inhibitory 
concentration (IC50) of 12.4 and 7.2 μg/mL for the extract and reference drug, respectively. After 24 
hours of exposure to the extract, the inoculated Vero cells showed lower parasitemia and no remarkable 
morphological changes.  
Conclusion: The findings demonstrate that the ethanol extract of P. sarmentosum leaves are active 
against toxoplasmosis in vitro. However, further studies are required to determine the therapeutic 
significance of these findings in vivo. 
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The sporozoan parasite, Toxoplasma gondii, is 
an intracellular coccidian tissue protozoa which is 
a common cause of toxoplasmosis in humans 
and animals, particularly immunocompromised 
hosts [1]. It is reported that approximately one 
third of the world’s current population has been 
infected with this parasite [2]. The World Health 
Organization considers toxoplasmosis one of the 
major parasitic diseases infecting humans in the 
developing countries [3]. This status is reflected 
by the parasite's worldwide distribution and 
broad range of intermediate hosts [4] that have 
resulted in the infection of up to 1 billion people 
[5]. Most toxoplasmosis cases are reported in 
South America, Middle East and other low-
income countries with high seropositivity against 
T. gondii infection in either normal or immune-
compromised hosts [6]. 
 
Toxoplasmosis is treated with a combination of 
sulfadiazine and pyrimethamine which are both 
key enzyme inhibitors in the biosynthesis of 
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pyrimidines [6]. However, these drugs cause 
adverse reactions, including the suppression of 
bone marrow, teratogenic effects in the first 
trimester of pregnancy, and sulfadiazine 
hypersensitivity [7]. Other drugs such as 
clindamycin, atovaquone, daspone, trimethoprim, 
pentamidine, and azithromycin have also been 
used, but side-effects such as diarrhoea, nausea, 
abdominal pain, cholestatic hepatitis, 
hepatomegaly, and hepatitis have been reported 
[8]. Cultural knowledge pertaining to the 
application of medicinal plants in the treatment of 
parasitic infection represents a vital role in the 
discovery of safe and natural chemotherapeutic 
agents against toxoplasmosis [9].  
 
Traditionally, the leaves of P. sarmentosum are 
used to treat malaria, coughs and colds, 
backache and joint pain, toothache, and worm 
infections [10]. Thus, the present study aims to 
investigate the anti-Toxoplasma activity of the 
ethanolic extract of P. sarmentosum leaves on T. 






The leaves of Piper sarmentosum were collected 
from the vicinity of Universiti Putra Malaysia. 
Authentication of the species was based on 
published taxonomical nomenclatures [11]. The 
leaves of Piper sarmentosum were rinsed 
thoroughly with multiple changes of distilled 
water and oven-dried at 50 °C before being 
ground into powder. Extraction was carried out 
by macerating 100 g of powdered leaves with 
500 mL of 95 % ethanol at room temperature for 
24 h. The extract was then filtered through 
Whatman no. 1 filter paper. After filtration, the 
extract was evaporated under reduced pressure 
using rotary evaporation. The RPMI-1640 
medium (Gibco BRL) was used as the solvent for 
the preparation of various dilutions of the 
ethanolic extract. Concentrated stock solution of 
each ethanolic extract was prepared by adding a 
known weight of each ethanolic extract to a 
known volume of RPMI-1640 medium, and then 
serially diluted (1:2) to obtain the working 
solutions at different final concentrations. 
 
Vero cell line 
 
Vero cells were maintained in a growth medium 
consisting of RPMI-1640 supplemented with 10 
% FBS (Gibco BRL), (Gibco BRL), 100 units/mL 
penicillin (Gibco BRL) and 100 μg/mL 
streptomycin (Gibco BRL). Clindamycin (Sigma-
Aldrich Corp) was used as the reference control 
drug. The cells were cultured and maintained at 
37 °C in a humidified 5 % CO2 incubator. 
 
Toxoplasma gondii RH strain 
 
The tachyzoites from the virulent RH strain of T. 
gondii were harvested from the peritoneal fluid 
layer of infected Balb/c mice in phosphate-
buffered saline (PBS), pH 7.2. The peritoneal 
fluid obtained was then centrifuged at 1500 rpm 
for 10 min at room temperature to remove host 
cells and debris as mice host cells were found in 
the peritoneal fluid layer. The pellet was washed 
twice with RPMI-1640 supplemented with 
glutamine (2 raM), penicillin (100 units/mL), and 
streptomycin (100 μg/mL). The tachyzoites T. 
gondii were inoculated to the Vero cell and grown 
in a 25mL tissue culture flask at 37°C in a 




Cytotoxicity of the ethanol extract of P. 
sarmentosum on Vero cells was determined 
using 3-(4, 5-dimethylthiazol-2-yl) -2,5-
diphenyltetrazolium bromide MTT assay which 
was published by Mosmann [12]; however, some 
modifications were made to this method. Vero 
cells were seeded at a density of 6 x104 cells/mL 
in each well of a 96-well plate containing 100μL 
of the growth medium. The plate was incubated 
at 37 ºC in a humidified 5 % CO2 incubator for 24 
hrs. The cells were treated with the ethanol 
extract of P. sarmentosum, which was serially 
diluted using the growth medium to obtain the 
various final concentrations of 200, 100, 50, 25, 
12.5, 6.25 and 3.125 μg/mL. 100 μL of each 
concentration was added into each respective 
96-well plate. In this study, clindamycin, a known 
drug for treating toxoplasmosis was used as the 
reference (positive) control drug, and RPMI was 
used as the control buffer. After 24 h of 
treatment, 200μL of the medium was aspirated 
out and 100 μL of MTT - PBS (5 mg/mL) solution 
in RPMI medium in the ratio of 1: 9 was added to 
each well. The plate was then covered with 
aluminium foil and incubated for 4hrs in a 37 ºC 
incubator. The medium was then discarded and 
100μL of DMSO was added into each well to 
solubilise the dark-blue MTT formazan salt. The 
optical density was measured at 570 nm 
absorbance using a Dynex Microplate Reader; 
higher concentrations can cause toxicity in Vero 
cells.  Growth inhibition (GI) was calculated as in 
Eq 1. 
 
GI (%) = {(At – Ac)/Ac}100 …………….. (1) 
 
where At and Ac are the absorbance of treated 
cells and control, respectively. 
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Determination of anti-Toxoplasma activity 
and cytotoxicity  
 
The inoculated Vero cells were harvested from 
the culture flask during the exponential growth of 
the cells at day 2, post-inoculation, with the cell 
density of 6 × 104 cells/mL cultured in 96-well 
plates. Following this, 3 × 105 mL of Toxoplasma 
gondii was added to each well with the parasite 
to cell ratio of 5:1 for Vero cell inoculation; this 
ratio was based on a previous study by Belloni 
[13]. Six hours after inoculation, the inoculated 
cells were washed twice with RPMI to remove 
any non-adherent parasites. After 18 hours of 
incubation, 200μL RPMI supplemented with 2 % 
FBS was added to each well following the 
methods developed by Sheng [14]. After 24 
hours of treatment, the anti- T. gondii activity and 
cytotoxicity of the ethanol extracts of P. 
sarmentosum were evaluated using the MTT 
method. The optical density reading on the 
microplate reader at 570nm was represented by 
the mean of three independent experiments. The 
median inhibitory concentration (IC50) value was 
calculated based on the concentration of ethanol 
extracts of P. sarmentosum and clindamycin that 
successfully inhibited 50 % of T. gondii. Anti-
Toxoplasma activity was expressed as selectivity 
index (SI) based on the mean of the IC50 values 
for Vero cells, relative to the mean of the IC50 
value of T. gondii as shown in in Eq 2 [15]. 
 
SI (%) = (V-IC50/T-IC50)100 ………. (2)  
 
where V-IC50 and T-IC50 are the median inhibitory 
concentrations required to inhibit Vero cell and T. 
gondii, respectively. 
 
Microscopic examination of tachyzoites 
 
Vero cells were cultured on a glass cover slip 
inside a 35mm petri dish until confluent, before 
being inoculated with 1×104 tachyzoites of T. 
gondii. After incubation for 4 hours, the 
monolayers formed on the glass cover slip were 
washed with a Hanks balanced salt solution 
(HBSS) (Gibco BRL).  The ethanol extract of P. 
sarmentosum and clindamycin was then added 
to each glass cover slip and incubated for 24 h at 
37 ºC. After incubation, the glass cover slips 
were washed twice with HBSS and fixed with 
methanol prior to staining with Giemsa (Sigma-
Aldrich Corp). All the prepared samples were 
observed using Nikon (model- Nikon Eclipse 50i) 
microscope and the images were captured using 
(NIS-Elements D, Japan). Qualitative analysis 





The statistical analysis was performed using 
Student’s t-test, and differences were considered 
significant at p < 0.05. The results were analysed 
using the Statistical Package for Social Sciences 
(SPSS) version 22 for Windows and are 






The results of in vitro anti-Toxoplasma activity 
against the T. gondii RH strain and selectivity 
index are summarized in Table 1 and Figure 1. 
Anti-Toxoplasma activity was found in all the 
samples tested as well as high mortality. The 
highest anti-Toxoplasma activity was found in 
Clindamycin with IC50 = 84.0 ± 1.15 μg/mL and 
Selectivity index = 11.67.  Anti-Toxoplasma 
activity of the ethanol extracts of P. sarmentosum 
was comparable to clindamycin with IC50 = 125.0 
± 1.53 μg/mL and selectivity index = 10.08. 
 
Morphology of anti-Toxoplasma in inoculated 
Vero cells 
 
Figures 2 and 3 illustrate the morphological 
effects of RPMI, clindamycin and P. 
sarmentosum extract on Vero cell and T. gondii 
inoculated Vero cells. After 24 hours, post-
inoculation, higher parasitemia were observed in 
the inoculated Vero cells (Figure 3). Tachyzoites 
of T. gondii could be observed inside the Vero 
cells; the tachyzoites were also adhered to the 
glass coverslip in the group treated with RPMI. 
However, when 50 μg/mL clindamycin and P. 
sarmentosum extract was added, the parasitemia 
drops and quantities of tachyzoites of T. gondii 
decreased sharply.  
 
Table 1: Cytotoxicity, in vitro activity and selectivity index of ethanol extract of P. sarmentosum (with clindamycin 
as control) against T. gondii tachyzoites 
 
Tested material Cytotoxicity (IC50, 
μg/mL) 
In vitro anti-Toxoplasma 
assay (IC50, μg/mL) 
Selectivity index (SI) 
Clindamycin 84±1.15 7.2± 1.53 11.67 
P. sarmentosum 125± 1.53 12.4± 1.00 10.08 
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Figure 1: Anti-Toxoplasma activity of ethanol extracts of P. sarmentosum and clindamycin against T. gondii 
(−−−− Clindamycin, ------Piper) 
 
 
Figure 2: Morphology of Vero cells after cytotoxicity testing with A) Clindamycin, B) P. sarmentosum leaves and 
C) RPMI medium. After 24 hours of exposure to 50 μg/mL of P. sarmentosum leaves extract and clindamycin. 
Vero cells showed no remarkable morphological changes. Stained using Giemsa stain. (200 X magnification) 
Scale 20 µm 
 
 
Figure 3: Morphology of Vero cells infected with T. gondii after adding a A) clindamycin, B) P. sarmentosum and 
C) RPMI medium. The tachyzoites of T. gondii (T) can be seen inside the inoculated Vero cells (V), as well as 
adhered to the glass cover slip. After 24 hours, post-inoculation and exposure to the 50μg/mL of P. sarmentosum 
extract and clindamycin, the inoculated Vero cells showed no remarkable morphological changes. Stained using 
Giemsa stain. A and B (400 X magnification), C (400 X magnification) Scale 10 µm 
 
Following the first 24 hours, the tachyzoites of T. 
gondii were infrequently observed in the 
inoculated Vero cells. No counting was involved 
in this process, the method was exclusively 
based on observation. There was no significant 
change in morphology of Vero cells after 
exposure to P. sarmentosum extract (Figure 2 
and Figure 3). 
DISCUSSION 
 
Parasitic diseases continue to have huge impact 
on human health, particularly in tropical regions 
[16]. New anti-parasitic drugs are urgently 
required in the treatment and control of parasitic 
infections such as toxoplasmosis [17]. The 
identification of an appropriate host to support 
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the growth of the parasite presents a major 
challenge in anti-parasitic drug discovery. 
Scientific evidence documenting the anti-
parasitic properties of medicinal plant extract, 
derives mainly from in vitro studies. The main 
advantage of in vitro studies in this context is the 
ability to detect directly anti-parasitic activity of 
these extracts or compounds. It is necessary to 
ensure that the plant extracts are not toxic to the 
host and will not affect host performance [18]. 
Plant extracts can be involved in anti-parasitic 
activity assessment only if the parasitized host 
benefits from prolonged   exposure to the extract. 
This net benefit can only be achieved if the 
antiparasitic properties of these extracts do not 
cause the adverse side effect on the host cell’s 
morphology and performance [19]. 
 
Studies by Villena [20], demonstrated the 
efficacy of sulfadiazine and pyrimethamine 
combination in the treatment of toxoplasmosis. 
This combination leads to remarkable synergistic 
activity against the replicating form of T. gondii 
cysts in tissue through the sequential inhibition of 
parasite dihydropteroate synthase (DHPS) and 
dihydrofolate reductase (DHFR). These two 
major enzymes are responsible for the synthesis 
of the folate compounds that are essential for the 
survival and replication of parasites. However, 
several failures have been reported in the 
treatment of toxoplasmic encephalitis, 
chorioretinitis and congenital toxoplasmosis. 
These failures, relating to the host, may be due 
to several factors such as drug intolerance, 
malabsorption, poor compliance to the 
development of drug-resistant parasites, or lower 
levels of susceptibility to the parasite strain [20]. 
The ethanolic extract of P. sarmentosum was 
tested for potential cytotoxic activity in vitro 
against Vero cells. It was concluded that the 
extract was not toxic to Vero cells with IC50 
values of more than 100 μg/ml (Figure 1). 
 
It is imperative to first establish whether the 
plant extracts affect Vero cell performance 
using the cytotoxicity study. Following the 
findings (Table 1), the ethanol extracts of P. 
sarmentosum were further tested for anti-
Toxoplasma and the potential (Figure 2). 
Anti-toxoplasma activity was found in the 
sample tested and high mortality of 
tachyzoites was observed. The extract also 
exhibited potential T. gondii inhibitory activity 
with the IC50 = 12.4 ± 2.08 μg/mL on the 
parasite growth (Figure 4). The results of the 
ethanol extracts of P. sarmentosum leaves 
were comparable to those of clindamycin 
(IC50 = 7.2 ± 1.52 μg/mL) (Figure 3 and 
Figure 4). A previous study by Saadatnia [21] 
concluded that the propagation of T. gondii 
parasites in Vero cells produced high yield 
and viability of tachyzoites, with minimal host 
cell contamination. Hence, Vero cells were 
used as the host cells for T. gondii in the 
present study to determine the anti-parasitic 
activity of the plant extracts.  
 
Following the addition of plant extracts to 
monolayers of Vero cells, the cells remained 
metabolically active and viable after being 
infected with Toxoplasma gondii. This study 
confirmed that Toxoplasma gondii could invade 
Vero cells and proliferate quickly; it also 
demonstrated that plant extracts effectively 
inhibited the growth of Toxoplasma gondii, and 
were less toxic to Vero cells than clindamycin. 
This finding signifies that P. sarmentosum could 
potentially be an alternative to clindamycin for 
the treatment of toxoplasmosis; this warrants 
further study.  
 
Normally the rapidly proliferating Toxoplasma 
gondii tachyzoites propagate by host cell lysis, 
regression, reattachment, and invasion of new 
host cells [22]. The significant changes observed 
in the morphology and confluence of Vero cells in 
an exclusively RPMI medium treated group 
(negative control) is likely due to the above fact. 
However, plant extract did not significantly affect 
the normal growth and morphology of the 
infected host cells, despite the potent anti T. 
gondii activities. The cells seemed to remain 
metabolically active and viable. In fact, cell 
proliferation and confluence was greater when 
compared to exposure to clindamycin. This 
observation verified that plant extracts had 
greater anti T. gondii activity and also had no 
selective toxicity against the infected host cells. 
Finally, this study confirms P. sarmentosum has 
potential as an alternative to clindamycin for the 




The ethanol leaf extract of P. sarmentosum 
shows potential anti-parasitic activity against T. 
gondii. Further study in the identification of the 
active compounds from this plant in Toxoplasma 
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